Integrase Inhibitors
Cabotegravir (CAB)
Summary
- Pharmacokinetic data are insufficient to make dosing recommendations for oral or long-acting injectable cabotegravir (CAB) during pregnancy or breastfeeding.
- Clinical data are insufficient to characterize the risk for congenital anomalies associated with in utero exposure to CAB. No reproductive toxicity or teratogenicity concerns were identified in animal studies.
Human Studies in Pregnancy
Pharmacokinetics
No studies have been conducted on the pharmacokinetics (PKs) of CAB and rilpivirine (RPV) with ongoing intramuscular (IM) injections during pregnancy. Clinical trial data reported to date are limited to pregnant women who stopped receiving CAB injections for the treatment or prevention of HIV once pregnancy was recognized and began an alternative oral antiretroviral regimen throughout the remainder of their pregnancies. From the ViiV-sponsored Phase 3 clinical trial of long-acting injectable CAB and RPV for the treatment of HIV, CAB PK data are available for three pregnant women after cessation of injections. In two of these women, both of whom maintained typical weight through delivery, CAB concentrations were predicted to remain therapeutic. Also, the rate of decline in concentrations during pregnancy in these two women was similar to the rate of decline in nonpregnant adults. The third pregnant woman had a faster rate of decline in CAB concentrations than expected; this woman had a low body mass index (BMI) (15.3 kg/m2), and her low body fat may have had altered absorption from the long-acting depot injection site.1 In HPTN 084, which assessed the efficacy and safety of long-acting CAB for HIV prevention, PK data are available in 26 participants who received at least one dose of CAB prior to the confirmation of pregnancy and discontinuation of CAB. The apparent terminal-phase half-life (t1/2app) in pregnant participants was comparable to nonpregnant individuals, although BMI greater than 27.2 was associated with longer CAB t1/2app.2 Physiologically based PK modeling predicts that pregnancy will have minimal influence on the PK of long-acting injectable CAB and that dose adjustments will not be indicated.3
Placental and Breast Milk Passage
Median (interquartile range 25–75) CAB maternal-to-fetal concentration ratio assessed using an ex vivo, dually perfused human cotyledon model was 10% (5–16), suggesting low placental transfer.4 No data are available describing breast milk passage of CAB in humans. See Rilpivirine for data about RPV.
Teratogenicity/Adverse Pregnancy Outcomes
The Antiretroviral Pregnancy Registry has not monitored sufficient numbers of first-trimester exposures to CAB to report on the risk of overall birth defects. Supplemental data from the Antiretroviral Pregnancy Registry on central nervous system (CNS) birth defect outcomes in three live births to women with periconception exposure to CAB reported one infant with a birth defect that was not a CNS defect nor a neural tube defect. These data are insufficient to make conclusions regarding the safety of CAB during pregnancy.5
In the Phase 2/3/3b trials of CAB and RPV, 26 of 325 women of reproductive potential became pregnant while exposed to CAB and RPV (5 oral, 21 long-acting injectable), resulting in 9 elective abortions, 6 spontaneous abortions, and 11 live births (1 oral, 10 long-acting injectable). Of the 11, there was 1 congenital ptosis in a preterm infant with intrauterine growth restriction.1 In HPTN 084, among 29 confirmed pregnancies (26 who received at least one injection), there were 4 pregnancy losses prior to 20 weeks, 1 between 20 to 36 weeks, and 22 live births. There were no congenital anomalies, preterm birth, or drug-related maternal or neonatal adverse events reported to date in the live births of infants from mothers who conceived while receiving IM injections of CAB alone.1,2 Increased adverse events (grade 1–3) during pregnancy were noted in the CAB arm of HPTN 084 (compared to the tenofovir disoproxil fumarate/emtricitabine arm), but were deemed unrelated to the study drug. See Rilpivirine for additional information about oral RPV.
Animal Studies
Carcinogenicity
CAB was neither mutagenic nor clastogenic in a series of in vitro and animal in vivo screening tests. Long-term carcinogenicity studies of CAB in mice did not show any carcinogenic potential at systemic exposures that were sevenfold (in females) or eightfold (in males) greater than human exposure at the recommended dose. In rats, no drug-related increases in tumor incidence were observed at CAB exposures up to approximately 26 times higher than those in humans at the recommended dose.6
CAB was not genotoxic in the bacterial reverse mutation assay, mouse lymphoma assay, or in vivo rodent micronucleus assay.7 See Rilpivirine for data about RPV.
Reproduction/Fertility
In rats, no effects on fertility were observed at CAB exposures at least 20 times greater than the exposure in humans at recommended doses. See Rilpivirine for data about RPV.
Teratogenicity/Adverse Pregnancy Outcomes
Studies in pregnant rats showed that CAB crosses the placenta and can be detected in fetal tissue. Treatment of rat dams with CAB during pregnancy and postpartum had no effects on fetal viability, although a minor decrease was observed in fetal body weight with exposures 28 times those seen in humans at the recommended dose. No drug-related fetal toxicities were observed with rat dam exposures approximately 13 times those seen in humans at the recommended dose, and no fetal malformations were observed at any rat dam dose. A delay in the onset of parturition and increases in the number of stillbirths and neonatal deaths were seen with exposure of rat dams to CAB at 28 times the human exposure with recommended doses, but not with exposure at 13 times the human exposure with recommended doses.
No drug-related fetal toxicities were observed after CAB exposures of rabbit dams of up to approximately 0.7 times those seen in humans at the recommended dose.6 See Rilpivirine for data about RPV.
Placental and Breast Milk Passage
Studies in lactating rats and their offspring indicate that CAB is present in rat milk. See Rilpivirine for data about RPV.
Excerpt from Table 14
Note: When using fixed-dose combination (FDC) tablets, refer to other sections in Appendix B and Table 14 in the Perinatal Guidelines for information about the dosing and safety of individual drug components of the FDC tablet during pregnancy.
Generic Name (Abbreviation) Trade Name |
Formulation | Dosing Recommendationsa | Use in Pregnancy |
---|---|---|---|
Cabotegravir (CAB) (CAB and RPV) Cabenuva CAB and RPV is a two-drug co-packaged product for IM injection. |
CAB
CAB RPV
|
Pregnancy PKs in Pregnancy
Dosing in Pregnancy
For guidance about the use of combination products in pregnancy, please see the specific sections on other components (i.e., RPV). Standard Adult Doses Oral Lead-in Therapy (Optional) CAB (Vocabria)
CAB (Apretude) Initiation:
Continuation Therapy
CAB and RPV (Cabenuva) Initiation:
Continuation Therapy
Changing Dosing Frequency and Managing Missed Doses |
No human data are available regarding placental passage. Insufficient data to assess for teratogenicity in humans. No evidence of teratogenicity in rats or rabbits. |
a Individual ARV drug doses may need to be adjusted in patients with renal or hepatic insufficiency (for details, see the Adult and Adolescent Guidelines, Appendix B, Table 11). b Placental transfer categories are determined by mean or median cord blood/maternal delivery plasma drug ratio: High: >0.6 Moderate: 0.3–0.6 Low: <0.3 KeyARV = antiretroviral; BMI = body mass index; CAB = cabotegravir; FDC = fixed-dose combination; IM = intramuscular; PK = pharmacokinetic; RPV = rilpivirine |
References
- Patel P, Thiagarajah S, Ford S, et al. Cabotegravir pharmacokinetic tail in pregnancy and neonatal outcomes. Abstract 775. Presented at: Conference on Retroviruses and Opportunistic Infections 2020. Boston, MA. Available at: https://www.croiconference.org/abstract/cabotegravir-pharmacokinetic-tail-in-pregnancy-and-neonatal-outcomes.
- Delany-Moretlwe S, Hughes J, Guo X, et al. Evaluation of CAB-LA safety and PK in pregnant women in the blinded phase of HPTN 084. Presented at: Conference on Retroviruses and Opportunistic Infections 2022. Virtual. Available at: https://www.croiconference.org/abstract/evaluation-of-cab-la-safety-and-pk-in-pregnant-women-in-the-blinded-phase-of-hptn-084.
- Atoyebi SA, Bunglawala FS, Cottura N, Camotti-Montanha M, Siccardi M, Waitt C. PBPK modelling of long-acting injectable cabotegravir in pregnancy. Presented at: Conference on Retroviruses and Opportunistic Infections 2022. Denver, CO. Available at: https://www.croiconference.org/abstract/pbpk-modeling-of-long-acting-injectable-cabotegravir-in-pregnancy.
- Pencole L, Le MP, Bouchet-Crivat F, Duro D, Peytavin G, Mandelbrot L. Placental transfer of the integrase strand inhibitors cabotegravir and bictegravir in the ex vivo human cotyledon perfusion model. AIDS. 2020;34(14):2145-2149. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32796211.
- Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry international interim report for 1 January 1989–31 January 2022. Wilmington, NC: Registry Coordinating Center; 2022. Available at: http://www.apregistry.com/forms/interim_report.pdf.
- Cabotegravir/Rilpivirine (Cabenueva kit) [package insert]. Food and Drug Administration. 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212888s005s006lbl.pdf.
- Edurant (Rilpivirine) [package insert]. Food and Drug Administration. 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202022s014lbl.pdf.
Integrase Inhibitors
Cabotegravir (CAB)
Excerpt from Table 14
Note: When using fixed-dose combination (FDC) tablets, refer to other sections in Appendix B and Table 14 in the Perinatal Guidelines for information about the dosing and safety of individual drug components of the FDC tablet during pregnancy.
Generic Name (Abbreviation) Trade Name |
Formulation | Dosing Recommendationsa | Use in Pregnancy |
---|---|---|---|
Cabotegravir (CAB) (CAB and RPV) Cabenuva CAB and RPV is a two-drug co-packaged product for IM injection. |
CAB
CAB RPV
|
Pregnancy PKs in Pregnancy
Dosing in Pregnancy
For guidance about the use of combination products in pregnancy, please see the specific sections on other components (i.e., RPV). Standard Adult Doses Oral Lead-in Therapy (Optional) CAB (Vocabria)
CAB (Apretude) Initiation:
Continuation Therapy
CAB and RPV (Cabenuva) Initiation:
Continuation Therapy
Changing Dosing Frequency and Managing Missed Doses |
No human data are available regarding placental passage. Insufficient data to assess for teratogenicity in humans. No evidence of teratogenicity in rats or rabbits. |
a Individual ARV drug doses may need to be adjusted in patients with renal or hepatic insufficiency (for details, see the Adult and Adolescent Guidelines, Appendix B, Table 11). b Placental transfer categories are determined by mean or median cord blood/maternal delivery plasma drug ratio: High: >0.6 Moderate: 0.3–0.6 Low: <0.3 KeyARV = antiretroviral; BMI = body mass index; CAB = cabotegravir; FDC = fixed-dose combination; IM = intramuscular; PK = pharmacokinetic; RPV = rilpivirine |
Download Guidelines
- Section Only PDF (151.04 KB)|spaceless
- Full Guideline PDF (6.28 MB)|spaceless
- Recommendations Only PDF (459.99 KB)|spaceless
- Tables Only PDF (907.8 KB)|spaceless